Quantcast

Latest Ustekinumab Stories

2015-02-04 08:28:53

Data expected to be released in Q1 2015 PETACH TIKVA, Israel, Feb.

2015-01-21 16:24:42

- Phase III data demonstrated Cosentyx resulted in clear or almost clear skin in the majority of patients with moderate-to-severe plaque psoriasis EAST HANOVER, N.J., Jan.

2014-12-11 16:24:58

First Presentation of Phase 3 Data From Brodalumab Psoriasis Program THOUSAND OAKS, Calif. and LONDON, Dec.

2014-11-25 16:27:52

Study Met All Primary Endpoints Against Stelara® (ustekinumab) and Placebo THOUSAND OAKS, Calif. and LONDON, Nov.

2014-11-18 08:31:20

Treatment for lifelong skin disease that affects nearly a million Canadians showed significant and clinically meaningful improvements in clinical studies Canadian approval comes

2014-11-16 16:21:13

- Secukinumab met primary endpoints demonstrating statistically significant improvements versus placebo in signs and symptoms of active psoriatic arthritis (PsA) in two pivotal Phase III studies

2014-11-11 16:25:45

Brodalumab Meets All Primary and All Key Secondary Endpoints THOUSAND OAKS, Calif. and LONDON, Nov.

2014-10-20 16:27:09

- Biologics License Application (BLA) for secukinumab, a "first-in-class" IL-17A inhibitor, is currently under FDA review with an anticipated action date in early 2015 EAST


Word of the Day
dynamitard
  • A political dynamiter.
The word 'dynamitard' is related to 'dynamite', which comes from a Greek root meaning 'power' and was coined by Alfred Nobel.